Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study including researchers in Nuffield Department of Population Health has found that government investment in healthcare research is good for the wider economy.

The research, supported by the NIHR Oxford Biomedical Research Centre (BRC), found that the return on investment in the Oxford BRC was 46% in terms of income and job creation alone.

The paper, ‘A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research Centres’, was published in the Plos One journal.

There are a number of methodologies for measuring research impact; one that has been widely used is the Payback Framework, which aims to capture the full life-cycle of biomedical research, from the initial concept to the eventual health, economic and societal benefits.

However, finding the data this framework requires over lengthy time lags is a major difficulty and, conscious that health benefits may not be realised for several years, the Oxford researchers decided to focus on the shorter-term economic returns by using an input-output analysis framework, which is often used to assess the impact of major government spending projects on other aspects of regional economies.

Read more (NIHR Oxford Biomedical Research Centre website)

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.